Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) EBIT Margin (2018 - 2025)

Historic EBIT Margin for X4 Pharmaceuticals (XFOR) over the last 6 years, with Q3 2025 value amounting to 1558.58%.

  • X4 Pharmaceuticals' EBIT Margin rose 46021300.0% to 1558.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 290.69%, marking a year-over-year increase of 20143000.0%. This contributed to the annual value of 1400.04% for FY2024, which is N/A changed from last year.
  • Latest data reveals that X4 Pharmaceuticals reported EBIT Margin of 1558.58% as of Q3 2025, which was up 46021300.0% from 1329.55% recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year EBIT Margin high stood at 12629.31% for Q2 2024, and its period low was 6160.71% during Q3 2024.
  • Moreover, its 4-year median value for EBIT Margin was 1979.76% (2022), whereas its average is 1141.61%.
  • Data for X4 Pharmaceuticals' EBIT Margin shows a peak YoY increase of 46021300bps (in 2025) and a maximum YoY decrease of -139588600bps (in 2025) over the last 5 years.
  • Over the past 4 years, X4 Pharmaceuticals' EBIT Margin (Quarter) stood at 2235.75% in 2022, then increased by 18bps to 2642.38% in 2023, then tumbled by -192bps to 2418.08% in 2024, then surged by 36bps to 1558.58% in 2025.
  • Its EBIT Margin stands at 1558.58% for Q3 2025, versus 1329.55% for Q2 2025 and 32.78% for Q1 2025.